Translational lung cancer research · 2026
Association of FDG PET/CT and immune profiling with pathologic complete response after neoadjuvant immunotherapy in stage II-III non-small cell lung cancer.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Lee Eun Seong, Park Saem Mul, Lee Seunghun, Kim Sehui, Choi Juwhan, Lee Jun Hee, Eo Jae Seon, Kim Hyun Koo, Yong Hwan Seok, Chen Chun-Jen J, Robinson Heidi, Dunbar P Rod, Lee Sung Yong
Аннотация
BACKGROUND: Neoadjuvant immunotherapy has emerged as a transformative approach for resectable non-small cell lung cancer (NSCLC). Pathologic complete response (pCR) after neoadjuvant therapy serves as a robust surrogate marker for early treatment efficacy and long-term outcomes. However, reliable noninvasive predictors of pCR before surgery remain an unmet clinical need. This study investigated the association between fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) parameters and tumor-infiltrating immune cell subsets in pre-treatment biopsies with pCR in patients with stage II-III NSCLC treated with immune checkpoint inhibitor (ICI)-based neoadjuvant therapy.
METHODS: We retrospectively analyzed 13 patients with stage II-III NSCLC who underwent ICI-based neoadjuvant therapy and baseline FDG PET/CT. pCR was assessed in resected surgical specimens. PET/CT parameters, including tumor-to-liver ratio (TLR) and maximum standardized uptake value (SUVmax), were evaluated before and after neoadjuvant treatment. Multiplex immunofluorescence (mIF) was performed on pre-treatment tumor biopsies to quantify tumor-infiltrating immune cell subsets and functional immune markers.
RESULTS: Eight patients (62%) achieved pCR. Compared with the non-pCR group, patients with pCR showed significantly lower post-treatment TLR (median 1.51 vs. 2.14, P=0.004) and a greater relative reduction in TLR (median 0.82 vs. 0.58, P=0.004). Pre-treatment biopsies from patients with pCR demonstrated higher infiltration of CD4+ T cells (P=0.04) and increased TIGIT expression on both CD8+ and CD4+ T cells. Pre-treatment TLR positively correlated with CD68+ macrophages and Ki67+ CD8+ T cells, while changes in TLR were significantly associated with TIGIT+ tumor-infiltrating T cells. During follow-up, recurrence occurred in only one patient in the non-pCR group.
CONCLUSIONS: Dynamic changes in PET/CT-derived TLR and immune biomarkers from pre-treatment biopsies were associated with pCR following neoadjuvant immunotherapy in stage II-III NSCLC. These findings support the complementary role of metabolic imaging and immune profiling in improving patient selection and perioperative decision-making.
METHODS: We retrospectively analyzed 13 patients with stage II-III NSCLC who underwent ICI-based neoadjuvant therapy and baseline FDG PET/CT. pCR was assessed in resected surgical specimens. PET/CT parameters, including tumor-to-liver ratio (TLR) and maximum standardized uptake value (SUVmax), were evaluated before and after neoadjuvant treatment. Multiplex immunofluorescence (mIF) was performed on pre-treatment tumor biopsies to quantify tumor-infiltrating immune cell subsets and functional immune markers.
RESULTS: Eight patients (62%) achieved pCR. Compared with the non-pCR group, patients with pCR showed significantly lower post-treatment TLR (median 1.51 vs. 2.14, P=0.004) and a greater relative reduction in TLR (median 0.82 vs. 0.58, P=0.004). Pre-treatment biopsies from patients with pCR demonstrated higher infiltration of CD4+ T cells (P=0.04) and increased TIGIT expression on both CD8+ and CD4+ T cells. Pre-treatment TLR positively correlated with CD68+ macrophages and Ki67+ CD8+ T cells, while changes in TLR were significantly associated with TIGIT+ tumor-infiltrating T cells. During follow-up, recurrence occurred in only one patient in the non-pCR group.
CONCLUSIONS: Dynamic changes in PET/CT-derived TLR and immune biomarkers from pre-treatment biopsies were associated with pCR following neoadjuvant immunotherapy in stage II-III NSCLC. These findings support the complementary role of metabolic imaging and immune profiling in improving patient selection and perioperative decision-making.